New analyses on retatruded, a dual stimulant for glucagon-like peptide-1 and gastric inhibitory polypeptide, suggest encouraging outcomes in addressing excess body fat and type 2 glucose intolerance. Initial information from clinical trials show considerable reductions in body bulk and bettered g